These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19800846)

  • 1. The potential usefulness of thrombelastography in quality monitoring and quality improvement of blood components.
    Seghatchian J
    Transfus Apher Sci; 2009 Dec; 41(3):227-8. PubMed ID: 19800846
    [No Abstract]   [Full Text] [Related]  

  • 2. Practical aspects of the self-assessment of the issue and administration of blood: a review of two hospitals' experiences.
    Shulman IA; Jones FS
    Am J Clin Pathol; 1997 Apr; 107(4 Suppl 1):S17-22. PubMed ID: 9124224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality requirements and quality assurance of leukocyte-depleted blood components.
    Myllylä G
    Curr Stud Hematol Blood Transfus; 1994; (60):111-22. PubMed ID: 8088164
    [No Abstract]   [Full Text] [Related]  

  • 4. [Quality assurance management system for therapy with blood and blood products].
    Diekamp U
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Oct; 33(10):664-5. PubMed ID: 9825053
    [No Abstract]   [Full Text] [Related]  

  • 5. Practical guidelines for applying statistical process control to blood component production.
    Beckman N; Nightingale MJ; Pamphilon D
    Transfus Med; 2009 Dec; 19(6):329-39. PubMed ID: 19761545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recommendations for use of leukocyte-depleted blood components].
    Danneskiold-Samsøe B; Dickmeiss E; Georgsen J; Heilmann C; Heslet L; Hovendal C; Jacobsen N; Jersild C; Johnsen H; Kirkegaard P
    Ugeskr Laeger; 1995 Mar; 157(12):1685-6. PubMed ID: 7740632
    [No Abstract]   [Full Text] [Related]  

  • 7. [Production and consumption of blood and blood products in Norway. Factors of quality assurance in transfusion medicine].
    Heier HE
    Tidsskr Nor Laegeforen; 1993 Jan; 113(1):18-22. PubMed ID: 8424244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Labile blood products and their preparation].
    Chabanel A; Folléa G
    Rev Prat; 2001 Jun; 51(12):1306-10. PubMed ID: 11503503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of an effective program for quality assurance and quality control in living cell therapy: a 2-year experience with autolymphocyte therapy.
    du Moulin GC; Liu V; Osband ME
    Transplant Proc; 1992 Dec; 24(6):2803-8. PubMed ID: 1465947
    [No Abstract]   [Full Text] [Related]  

  • 10. [Safety of plasma products may be improved].
    Wahlberg T
    Lakartidningen; 1995 Dec; 92(51-52):4869-70. PubMed ID: 8544500
    [No Abstract]   [Full Text] [Related]  

  • 11. Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force.
    Transfus Med; 1998 Mar; 8(1):59-71. PubMed ID: 9569462
    [No Abstract]   [Full Text] [Related]  

  • 12. [Establishing a quality assurance system in transfusion medicine exemplified by the Heidelberg University Blood Bank].
    Stahl D; Kluge A; Roelcke D
    Infusionsther Transfusionsmed; 1995 Dec; 22(6):364-77. PubMed ID: 8589598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk management from the perspective of the hematologist].
    Gossrau E
    Z Arztl Fortbild Qualitatssich; 2003 Nov; 97(8-9):618-21. PubMed ID: 14710657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The thromboelastography and the thromboelastograph technique.
    Chandler WL
    Semin Thromb Hemost; 1995; 21 Suppl 4():1-6. PubMed ID: 8747681
    [No Abstract]   [Full Text] [Related]  

  • 15. [Blood transfusion and monitoring. Blood products for transfusion. Indications].
    Gaspard M
    Soins; 1996 Apr; (605):18-9. PubMed ID: 8716243
    [No Abstract]   [Full Text] [Related]  

  • 16. [Thromboelastography - useful in cases of bleeding?].
    Espinosa A; Ekeland MS
    Tidsskr Nor Laegeforen; 2017 Mar; 137(5):367-370. PubMed ID: 28272567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Guidelines of the German Medical Association for Therapy with Blood Components and Plasma Derivatives--an introduction. Evidence-based recommendations for the risk-benefit analysis in hemotherapy].
    Heim MU
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2009 Mar; 44(3):186-97; quiz 199. PubMed ID: 19266420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in QA of leucodepleted blood component and current standard(s). Challenges in quality assurance of leukoreduced components.
    Dumont LJ
    Transfus Sci; 1998 Dec; 19(4):377-80. PubMed ID: 10351162
    [No Abstract]   [Full Text] [Related]  

  • 19. [Checking of blood product in hospital].
    Girard A
    Transfus Clin Biol; 2004 Oct; 11(4):205-9. PubMed ID: 15564102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quality control in autologous blood donation and transfusion].
    Dietrich G; Kretschmer V
    Beitr Infusionsther; 1991; 28():348-55. PubMed ID: 1725653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.